UT Health Science Center-San Antonio: Study Results Show Immunotherapy Before and After Surgery for Advanced Melanoma Lowers Recurrence Risk
March 14, 2023
March 14, 2023
SAN ANTONIO, Texas, March 14 (TNSjou) -- The University of Texas Health Science Center at San Antonio issued the following news release:
Mays Cancer Center at UT Health San Antonio melanoma expert Monte Shaheen, MD, was part of a team of investigators that conducted a phase II clinical trial funded by the National Cancer Institute (NCI) to determine the efficacy and safety of administering the immunotherapy drug pembrolizumab before and after surgery in high-risk melanoma patients.< . . .
Mays Cancer Center at UT Health San Antonio melanoma expert Monte Shaheen, MD, was part of a team of investigators that conducted a phase II clinical trial funded by the National Cancer Institute (NCI) to determine the efficacy and safety of administering the immunotherapy drug pembrolizumab before and after surgery in high-risk melanoma patients.< . . .